Topotecan (NSC609699) HCl

For research use only. Not for use in humans.

目录号:S1231 别名: Nogitecan HCl, SKFS 104864A 中文名称:盐酸拓扑替康

Topotecan (NSC609699) HCl Chemical Structure

CAS No. 119413-54-6

Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) 是一种拓扑异构酶I抑制剂,作用于MCF-7 Luc细胞和DU-145 Luc细胞,无细胞试验中IC50分别为13 nM和2 nM。Topotecan HCl 可诱导自噬和凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1872.81 现货
RMB 1466.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Topotecan (NSC609699) HCl发表文献34篇:

产品安全说明书

Topoisomerase抑制剂选择性比较

生物活性

产品描述 Topotecan HCl (NSC609699, Nogitecan, SKFS 104864A) 是一种拓扑异构酶I抑制剂,作用于MCF-7 Luc细胞和DU-145 Luc细胞,无细胞试验中IC50分别为13 nM和2 nM。Topotecan HCl 可诱导自噬和凋亡。
特性 Topotecan是camptothecin的水溶性衍生物。
靶点
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
体外研究

Topotecan对DU-145 Luc和MCF-7 Luc细胞具有很强的药物活性。[1] DNA复制期间,Topotecan通过稳定拓扑异构酶I和DNA之间的共价复合物,并防止酶联单链DNA断裂后再连接,引起细胞毒性。在耐辐射的人B系急性淋巴细胞性白血病(ALL)细胞中,Topotecan稳定拓扑异构酶I/DNA可裂解复合物,尽管bcl-2高度表达,也能够引起快速的细胞凋亡,并且剂量依赖性抑制ALL细胞的克隆生长。 [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells NUT4ZpFCS3m2b4TvfIlkyqCjc4PhfS=> M4fkN|czKGh? NFLFc|dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFM2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJIlkPTB;MTDuUS=> NHTrcmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO3NVE5Oyd-MkCzO|EyQDN:L3G+
human Bel7402 cells MV7DfZRwfG:6aXRCpIF{e2G7 NX7aUYJJQTZiaB?= MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDC[Yw4PDB{IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU4zKG6P MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTF4NUG0OEc,OTVzNkWxOFQ9N2F-
human HCT8 cells MXfDfZRwfG:6aXRCpIF{e2G7 MVW5OkBp NEDlWoREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU42KG6P MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTF4NUG0OEc,OTVzNkWxOFQ9N2F-
human MCF7 cells NGKzR5VEgXSxdH;4bYPDqGG|c3H5 NWDveG9yQTZiaB?= NHLLd2xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9NU45KG6P MoLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human A549 cells NX;wOJRHS3m2b4TvfIlkyqCjc4PhfS=> NEnOUmg6PiCq MkTvR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOuNkBvVQ>? MnW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzNkWxOFQoRjF3MU[1NVQ1RC:jPh?=
human colon carcinoma SW620 cell M{LuRmN6fG:2b4jpZ:Kh[XO|YYm= Mn[1R5l1d3SxeHnjJJBwfGWwdHnheIlwdiCxZjDUc5BwfGWlYX6gLHRRMSCkeTD0bIUh[2:vcH;1coQhcW5iaIXtZY4h[2:ub36gZ4Fz[2mwb33hJHNYPjJyIHPlcIwhdGmwZTygTWM2OD1|LkKgcm0> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjRyOEewO{c,OTJ2MEi3NFc9N2F-
human MESSA cells MoPzR5l1d3SxeHnjxsBie3OjeR?= M1\4[|czKGh? NWnLcXZLS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVU1GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVQhdk1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human BGC823 cells NVz2dnhbS3m2b4TvfIlkyqCjc4PhfS=> NHHTeYE6PiCq M4XoSWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGJISzh{MzDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVQvOyCwTR?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTF4NUG0OEc,OTVzNkWxOFQ9N2F-
human Ketr3 cells M{izVWN6fG:2b4jpZ:Kh[XO|YYm= MkTUPVYhcA>? MlrGR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4V1ejNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20Mlkhdk1? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTF4NUG0OEc,OTVzNkWxOFQ9N2F-
LOX cells NFH1flFEgXSxdH;4bYPDqGG|c3H5 MlPsR5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEyRWDDj[YxteyBqbXXsZY5wdWFrIH;mJIh2dWGwIIT1cY9zKGOnbHygcIlv\XNiYomgeZNqdmdiTWTUJIF{e2G7LDDJR|UxRTVibl2= MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwPzh3M{OzNUc,Pzh3M{OzNVww[T5?
human A549 cells NIjYbHJHfW6ldHnvckBie3OjeR?= Mo\QOEBp NWjrbndWSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJyN{e0PEc,OTh{MEe3OFg9N2F-
human H69 cells MWjDfZRwfG:6aXRCpIF{e2G7 NGrOU2I4OiCq MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTZibl2= M1HEWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human A2780 cells NH7GbmhEgXSxdH;4bYPDqGG|c3H5 NIS3dZg4OiCq NYHCem9oS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNib4\ldoV5eHKnc4Ppcoch[WyyaHG1ZoV1[TNiaX70[YdzcW5iYYPz[ZN{\WRiYYOgZ4VtdCC|dYL2bZZidCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVYhdk1? Mo\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
human LNCAP cells MnPoR5l1d3SxeHnjxsBie3OjeR?= NHu0UVU4OiCq MYLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;OTDuUS=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
human HOP62 cells M2[0SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXyxbWh6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SNkKgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N NF72b4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmwPVI4QSd-MkW5NFkzPzl:L3G+
human MCF7 cells NI\1NJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXnxZYJkT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= NVvOTGRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NFkzPzlpPkK1PVA6Ojd7PD;hQi=>
human UACC62 cells NX7pR2t6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1TuWGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHVCS0N4MjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
human DU145 cells NH;QPINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDEWVE1PSClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlyOUK3PUc,OjV7MEmyO|k9N2F-
LoVo cell line MV7DfZRwfG:6aXRCpIF{e2G7 M{fEdmN6fG:2b4jpZ{Bxd3SnboTpZZRqd25ib3[gWI9xd3SnY3HuJEhVWCliYomgeIhmKGOxbYDveY5lKGmwIDjoeY1idiClb3zvdoVkfGGuIHPhcoNmeiCOb2\vJINmdGxibHnu[UwhUUN3ME2xNU43KG6P NHjEO|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkSwPFcxPyd-MUK0NFg4ODd:L3G+
human lymphoblast tumor cell line RPM18402 NXnKPGZHS3m2b4TvfIlkyqCjc4PhfS=> Mk\5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJlueGixYnzhd5QhfHWvb4KgZ4VtdCCuaX7lJHJRVTF6NECyMEBKSzVyPUGyJI5O M1\qSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{M{myO|Q2Lz5zMkO5Nlc1PTxxYU6=
human HL60 cells NHfGb4JHfW6ldHnvckBie3OjeR?= MofTRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwQVEzKG6P M3\kZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUSxOFg{Lz5zOUW0NVQ5OzxxYU6=
human A375 cells MYPDfZRwfG:6aXRCpIF{e2G7 MoDlO|IhcA>? MmruR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MUOgcm0> MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2MU[3OEc,OjF|NEG2O|Q9N2F-
COR-L23/P cell Mn;CR5l1d3SxeHnjxsBie3OjeR?= MoHDR5l1d3SxeHnjbZR6KG2nYYP1doVlKHW|aX7nJJRp\SCFT2KtUFI{KHCjcnXueIFtKCiFT2KtUFI{N1BrIHj1cYFvKG6xbjDzcYFtdCClZXzsJIx2dmdiY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1zMz6yJI5O MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOThyNkeyOEc,OTF6ME[3NlQ9N2F-
human NCI-H460 cells M3HLd3Bzd2yrZnXyZZRqd25iYYPzZZk> M2jwWFczKGh? M3f1WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINwfWy2ZYKgZ492dnSncjDhcoFtgXOrczygTWM2OD1zNjDuUS=> NV;VTXJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFM{PjlpPkKxO|g{OzZ7PD;hQi=>
human MOLT4 cells NFjI[mtEgXSxdH;4bYPDqGG|c3H5 NEnVPW44OiCq M3TpS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1QVFR2IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NVkhdk1? NHzyeFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFczPSd-MkS5NFA4OjV:L3G+
human LoVo cells NGTldGVEgXSxdH;4bYPDqGG|c3H5 NUfRNIdOPzJiaB?= M4X0N2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yNEBvVQ>? MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN5MUG4N{c,OjB|N{GxPFM9N2F-
RPM18402 tumor cell line NFLMbGRRem:uaX\ldoF1cW:wIHHzd4F6 NHS0Om5Ed26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;uJIlvKFKSTUG4OFAzKHS3bX;yJINmdGxibHnu[UwhUUN3ME2yNEBvVQ>? MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2OEK5NlkoRjF3NEiyPVI6RC:jPh?=
human SN12C cells MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MliyS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P M4nMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUC5Nlc6Lz5{NUmwPVI4QTxxYU6=
human RPMI8226 cells MV;DfZRwfG:6aXRCpIF{e2G7 MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSVG1KQDJ{NjDj[YxteyCkeTDNWHQhdWW2aH;kMEBKSzVyPUKxJI5O NHrONW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCxNlk6Pid-MUmwNVI6QTZ:L3G+
HT-29 cells MY\DfZRwfG:6aXRCpIF{e2G7 MknnR5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEiWLUK5JINmdGy|KHPvcI9vMSCxZjDoeY1idiC2dX3vdkBk\WyuIHzpcoV{KGK7IIXzbY5oKE2WVDDhd5NigSxiSVO1NF0zPSCwTR?= NIO0WVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi95OEWzN|MyLz55OEWzN|MyRC:jPh?=
SK-BR-3 cells M3LtWmN6fG:2b4jpZ:Kh[XO|YYm= NHfNWI5KdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBjemWjc4SgZ4Fv[2W{IHPlcIwhdGmwZTCoV2suSlJvMzmsJGlEPTB;Mk[gcm0> NIe5blU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
HeLa cells M13vOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmH2S5Jwf3SqIHnubIljcXSrb36gc4YhUGWOYTDj[YxteyCjZoTldkA1KGSjeYOsJGdKPTB;M{Cgcm0> NIK0bY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxPFU5Oid-MUe0NVg2QDJ:L3G+
UACC 62 cells MU\DfZRwfG:6aXRCpIF{e2G7 MoXxWIV{fGWmIHnuJJZqfHKxIH\vdkBkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckB1fW2xcjDj[YxtKGyrbnWgWWFESyB4MjCocYVt[W6xbXGpMEBIUTVyPUOwJI5O M3HFXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{G0OVAzLz5zMEexOFUxOjxxYU6=
human HCT116 cells MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVG3bFNJT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWMUG2JINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygS2k2OD1|MDDuUS=> M4S5W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUC5Nlc6Lz5{NUmwPVI4QTxxYU6=
human lung cancer cell line (H128) MljuR5l1d3SxeHnjxsBie3OjeR?= MnzyTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiKMUK4LUwhUUN3ME2zNUBvVQ>? NFTRUYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human MES-SA/Dx5 cells NV63OXRJS3m2b4TvfIlkyqCjc4PhfS=> NXrZelE5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2zN{BvVQ>? M2DFdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{SxOlc1Lz5{MUO0NVY4PDxxYU6=
human A2780 cells MmrUR5l1d3SxeHnjxsBie3OjeR?= NV7Xb4ZYPzJiaB?= MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUOzJI5O MoXoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3NlUoRjJ2OUCwO|I2RC:jPh?=
human MDA-MB-435 cells NFXTbZhEgXSxdH;4bYPDqGG|c3H5 MWi3NkBp MkDrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVA:OzRibl2= M{\4[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OE[3NFE6Lz5{Mki2O|AyQTxxYU6=
human stomach cancer cell line (MKN45) MWLDfZRwfG:6aXRCpIF{e2G7 NYL5coNNUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;M{igcm0> NEHtWIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human KB3-1 cells M33O[WN6fG:2b4jpZ:Kh[XO|YYm= MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NECgcm0> NYrqRXI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4Nlk{OzRpPkG4PFI6OzN2PD;hQi=>
mouse P388 cells M3rIbmN6fG:2b4jpZ:Kh[XO|YYm= M4fCcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJHA{QDhiY3XscJMh[W[2ZYKgUXRVKGG|c3H5MEBKSzVyPUS1JI5O MlzmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MkmzN|QoRjF6OEK5N|M1RC:jPh?=
A427 human lung carcinoma NEf3WnBRem:uaX\ldoF1cW:wIHHzd4F6 MnfSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgcYVie3W{ZXSgZYdicW6|dDDBOFI4KGi3bXHuJIx2dmdiY3HyZ4lvd22jLDDJR|UxRTR7IH7N MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86QDd4MUGxK|46QDd4MUGxQE9iRg>?
human U251 cells M1zoT2Z2dmO2aX;uJIF{e2G7 MYW2MVI1KGh? Ml\kTY5pcWKrdHnvckBw\iC2b4DvbZNwdWW{YYPlMVEhcW5iaIXtZY4hXTJ3MTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZvMXHsdIhiKGGlY4XteYxifGmxbjDpckBvfWOuZXHyJIV5fHKjY4SgZYZ1\XJiNjD0c{AzPCCqcoOgZpkhcW2vdX7vZoxwfCCjbnHsfZNqeyxiRVO1NF02PCCwTR?= NFfVXmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkOwOVYyOid-MkKzNFU3OTJ:L3G+
human colon cancer cell line (WiDr) NULVU3dKS3m2b4TvfIlkyqCjc4PhfS=> MoLYTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN|NEW2PUc,OTF|M{S1Olk9N2F-
human HepG2 cells NGXOb4hEgXSxdH;4bYPDqGG|c3H5 NHvxVG41KGSjeYO= NVvPb2NIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KE2WVDDhd5NigSxiSVO1NF03OCCwTR?= NGjjcHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1OFkxPid-MUi1OVQ6ODZ:L3G+
human KB cells MV7DfZRwfG:6aXRCpIF{e2G7 NUfJRZR[PzJiaB?= MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB5MjDodpMhe3WuZn;ybI9l[W2rbnWgRkBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUC9OlIvPSCwTR?= NE\3Xmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPFQ2Pid-MkWwNFg1PTZ:L3G+
human HCT8 cells NIrWbGJEgXSxdH;4bYPDqGG|c3H5 MlLxN{Bl[Xm| NF\Vd2VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1? M3PhT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{myOVQ2Lz5{MEO5NlU1PTxxYU6=
human GBM2 cells NIfobmNRem:uaX\ldoF1cW:wIHHzd4F6 MVy3NkBp MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlE{KM7:TR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3NUWzNkc,OjZ|NUW1N|I9N2F-
SK-MEL-2 cells NUjaVJBYS3m2b4TvfIlkyqCjc4PhfS=> M2m1OFczKGh? NUT6[Gk5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW0tvTVXMMVIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTBwMUSg{txO NF3kWZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0NVY4PCd-MkGzOFE3PzR:L3G+
human IGROV1 cells NFfWWmdEgXSxdH;4bYPDqGG|c3H5 M1nUWlczKGh? Mnq0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTWdTV1ZzIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2wMlE3KM7:TR?= MnnYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|NEG2O|QoRjJzM{SxOlc1RC:jPh?=
human U87 cells MVLQdo9tcW[ncnH0bY9vKGG|c3H5 MXS0PEBp M1jZd2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOkDPxE1? NWjH[WtwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NlY5OThpPkK0PFI3QDF6PD;hQi=>
human HT1080 cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 MWS0PEBp NVPLUGN{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWFExQDBiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OD1yLkG4JO69VQ>? NEDNdno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSwPFgyPSd-Mk[0NFg5OTV:L3G+
human Hep3B cells NXm5TXFlWHKxbHnm[ZJifGmxbjDhd5NigQ>? MoPSO|IhcA>? MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincEPCJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC[VGSgZZN{[XluIFfJOVA:OC5{MjFOwG0> M2DVTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{m2PVU3Lz5zOUe5Olk2PjxxYU6=
human GBM3 cells MYnQdo9tcW[ncnH0bY9vKGG|c3H5 M3O2VlczKGh? NIHF[FFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFfCUVMh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JHdUXC1zIH3leIhw\CxiSVO1NF0xNjN6IN88US=> M1fPclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{W1OVMzLz5{NkO1OVU{OjxxYU6=
human KBVIN cells M{faPWN6fG:2b4jpZ:Kh[XO|YYm= MYC3NkBp NEX5NGlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSl[LTjDj[YxteyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwQVAvPCEQvF2= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR|OEe2PUc,OjV2M{i3Olk9N2F-
human GBM1 cells MYTQdo9tcW[ncnH0bY9vKGG|c3H5 NUDhZ2xWPzJiaB?= Mk[wRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2xJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE41PiEQvF2= MmDZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|NUW1N|IoRjJ4M{W1OVMzRC:jPh?=
human U937 cells MWjDfZRwfG:6aXRCpIF{e2G7 MWW0PEBp MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIV5eHKnc4PpcocheDV|IH31eIFvfCCjZoTldkA1QCCqcoOgZpkhW1KEIHHzd4F6KO,:jDDJR|UxRTFwMTFOwG0> NUGwOWZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3NVU{OTlpPkG5O|E2OzF7PD;hQi=>
Caco2 MV7DfZRwfG:6aXPpeJkh[XO|YYm= NEP5UYszPCCqcoO= MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDZYNwOiClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuNVE6|ryPLh?= NF36VVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
Jurkat NGP6ZmpEgXSxdH;4bYNqfHliYYPzZZk> NXu3bFg5OjRiaILz NHr3cWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBLfXKtYYSgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjF{N988UU4> MlvzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
A375 Mn\sR5l1d3SxeHnjbZR6KGG|c3H5 MX6yOEBpenN? M{D0T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE{PzViY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlE3Os7:TT6= NF72dXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
HeLa NGjuXpdEgXSxdH;4bYNqfHliYYPzZZk> Ml3DNlQhcHK| MoCyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUCuN|jPxE1w M2Dk[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
MDA-MB-231 MmrjR5l1d3SxeHnjbZR6KGG|c3H5 Mmf6NlQhcHK| MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC52N{ROwG0v MnTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OECxNVgoRjJ2OUiwNVE5RC:jPh?=
NCI-H460 NXX5TZd{SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MoPhNUBpeg>? MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IIPoc5J1KHSncn2g[Zhxd3O3cnWg[o9zKDFiaIKgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGmwIHTyeYcu\nKnZTDt[YRqfW1uIFnDOVA:OC54Md88UU4> Mo\GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{C3NlAoRjF7NUOwO|IxRC:jPh?=
HCT8 NXHGbpBlSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NWnNdZlqPDhiaILz M2rte2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUPEBk\WyuczDh[pRmeiB2ODDodpMh[nliQ1PLPEBie3OjeTygTWM2OD1zLki3Oe69VS5? MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEGzPVUoRjJ3NEixN|k2RC:jPh?=
KB MmTFRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MWC0PEBpenN? NXvFN21FSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRkBk\WyuczDh[pRmeiB2ODDodpMh[nliQ1PLPEBie3OjeTygTWM2OD1{LkK4Nu69VS5? M1;ablxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEixN|k2Lz5{NUS4NVM6PTxxYU6=
SGC7901 NHryNHFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NVT4bIh6PDhiaILz MnvnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVR1O3PVAyKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG|c3H5MEBKSzVyPUKuNlkz|ryPLh?= NIDtVpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS4NVM6PSd-MkW0PFE{QTV:L3G+
HepG2 NGDOeZRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXvLWHVzPDhiaILz NWrHNJBDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bi\nSncjC0PEBpenNiYomgR2NMQCCjc4PhfUwhUUN3ME20MlIxQM7:TT6= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR6MUO5OUc,OjV2OEGzPVU9N2F-
MDA-MB-231 Mlz1RZBweHSxc3nzJIF{e2G7 MYfJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNicEWzJJBpd3OyaH;yfYxifGmxbjDheEBU\XJzNTDifUBY\XO2ZYLuJIJtd3S2aX7nJIFv[Wy7c3nz NYXpOlNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PFAyOThpPkK0PVgxOTF6PD;hQi=>
HeLa M{nNU2Fxd3C2b4Ppd{Bie3OjeR?= NFTOdocxNjhidH:gNU43KHWP NGnjVGYzPCCqcoO= NUDzZYVkUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHO7boTo[ZNqeyCjdDCwMlghfG9iMT62JJVOKGGodHXyJFI1KGi{czDifUBDemSXIIP0ZYlvcW6pLXLhd4VlKEWOSWPB NH34TXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm4NFEyQCd-MkS5PFAyOTh:L3G+
MDA-MB-231 Ml7tRZBweHSxc3nzJIF{e2G7 MkXUNE45KHSxIEGuOkB2VQ>? M17CPFI1KGi{cx?= MoTBTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhTE6DIIP5cpRp\XOrczDheEAxNjhidH:gNU43KHWPIHHmeIVzKDJ2IHjyd{BjgSCEcnTVJJN1[WmwaX7nMYJie2WmIFXMTXNC M4nofFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUiwNVE5Lz5{NEm4NFEyQDxxYU6=
A375 MlvpRZBweHSxc3nzJIF{e2G7 MnfSNE45KHSxIEGuOkB2VQ>? NVT1VIpyOjRiaILz NWTGblhCUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDBN|c2KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gSG5CKHO7boTo[ZNqeyCjdDCwMlghfG9iMT62JJVOKGGodHXyJFI1KGi{czDifUBDemSXIIP0ZYlvcW6pLXLhd4VlKEWOSWPB NWf5SpdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PFAyOThpPkK0PVgxOTF6PD;hQi=>
Caco2 NITlVZRCeG:ydH;zbZMh[XO|YYm= NGK5fWkxNjhidH:gNU43KHWP M{Dm[FI1KGi{cx?= MXnJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEOjY3:yJINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiRF7BJJN6dnSqZYPpd{BifCByLkigeI8hOS54IIXNJIFnfGW{IEK0JIhzeyCkeTDCdoRWKHO2YXnubY5oNWKjc3XkJGVNUVOD MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
A375 MX7BdI9xfG:|aYOgZZN{[Xl? M3Tp[2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUO3OUBk\WyuczDhd5Nme3OnZDDhd{BxPTNicHjvd5Bpd3K7bHH0bY9vKGG2IGPldlE2KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl6MEGxPEc,OjR7OECxNVg9N2F-
TC32 NXrsXIpDeUiWUzDhd5NigQ>? NF3EeFVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?= NUTrdJpDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY MmDPdWhVWyCjc4PhfS=> M2jDW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy| M3:wb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2 NXfnRWt5eUiWUzDhd5NigQ>? NWi4b21[eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> M4X3UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MlHOdWhVWyCjc4PhfS=> NF3wZWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC MlnKdWhVWyCjc4PhfS=> NF3H[lNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NXLXe|lReUiWUzDhd5NigQ>? MkXOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| M1n3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 M1\SdJFJXFNiYYPzZZk> NEHCNJlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Saos-2 M3O3RpFJXFNiYYPzZZk> NGT6[XhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz NGT4bYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH MUTxTHRUKGG|c3H5 MkDJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= NHnLWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 MX;xTHRUKGG|c3H5 MlnsdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NE\VbGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 MlHqdWhVWyCjc4PhfS=> NFuzT2hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NWLad2czRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NHTDO|JyUFSVIHHzd4F6 NV7r[3AxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NHSwcGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MoTDdWhVWyCjc4PhfS=> MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NIHFXHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 Mn\SdWhVWyCjc4PhfS=> NYrFVGZUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MXvxTHRUKGG|c3H5 M120UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) Moj0dWhVWyCjc4PhfS=> NXXWcmF2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NX\JXZpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41 NEDZeYFyUFSVIHHzd4F6 NFfvVHFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?= NFzIR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M1jKNpFJXFNiYYPzZZk> MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM> NWf5SIZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673 MXrxTHRUKGG|c3H5 NH3QXlRyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBCPjd|IHPlcIx{MQ>? M3Xn[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MnTKdWhVWyCjc4PhfS=> MkLudWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>? NWr6TGtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 M4rqS5FJXFNiYYPzZZk> NGr0epdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>? NYXuWY1kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 Ml7ydWhVWyCjc4PhfS=> M3\xO5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{ NYPBU5VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NYrSe5ZCeUiWUzDhd5NigQ>? NGPyb3lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBFSU:\IHPlcIx{ M2i0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MVXxTHRUKGG|c3H5 MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{ NVvnUXd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NVH5Xo9XeUiWUzDhd5NigQ>? NYXCT2pCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NUHxc29{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 MUnxTHRUKGG|c3H5 NYfzbmQyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TC32 NEjaVo5yUFSVIHHzd4F6 M{Hhc5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> MknjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) MW\xTHRUKGG|c3H5 MkLYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUWchPjNiKE[tWGchWiliY3XscJM> M4PqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS MkjjdWhVWyCjc4PhfS=> NGjMTZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN? M1q2TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 Mmq0dWhVWyCjc4PhfS=> M1vmWpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> NXH1Om1PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD NXPEWHRHeUiWUzDhd5NigQ>? Mn\CdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO= MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh18 MnO3dWhVWyCjc4PhfS=> M4LyVJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM> NWXPN3dORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30 NH;0W49yUFSVIHHzd4F6 M4ixcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM> M4\JTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 NYfhdo91eUiWUzDhd5NigQ>? NUHZWZM{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy| NY\qb2V1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M4j5UJFJXFNiYYPzZZk> M3zo[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG9JWy13MDDj[Yxtew>? Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH Mo\IdWhVWyCjc4PhfS=> MnvwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>? NVXH[5d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH NGXvb4pyUFSVIHHzd4F6 M3\jTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= Ml70QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NGXIfZFyUFSVIHHzd4F6 NIrLN3dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MnLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Daoy MoG3dWhVWyCjc4PhfS=> Ml:1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBF[W:7IHPlcIx{ NETv[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
TC32 NUi4eVFGeUiWUzDhd5NigQ>? NGLvT4RyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJINie3Cjc3Wgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{ MoPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
TC32 MWXxTHRUKGG|c3H5 MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM> M{G2bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) M1XzTJFJXFNiYYPzZZk> NYrKfYFJeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= MmeyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NH;jUnNyUFSVIHHzd4F6 MmPLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohV3K2aH;nc45idCB|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBTTCClZXzsdy=> M1fXclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3 / p62 ; 

PubMed: 23024792     


The indicated cells were treated with the indicated concentrations of topotecan for 24 h. The lysates were analysed by immunoblotting with The LC3 and P62 antibodies.

p53 / sesn2 / p-AMPK ; 

PubMed: 23024792     


HCT116 and LS-174T cells were treated with various concentrations of TPT for 24 h. The levels of P53, sestrin2 and p-AMPK were analysed by immunoblotting. 

23024792
Growth inhibition assay
Cell viability ; 

PubMed: 28544814     


Dose-response curves for topotecan (panel A) were determined in neuroblastoma cell lines The IC50 for the drugs are indicated. Changes in LAN-1 cell viablity as a function of different topotecan exposure times (panel B) were determined.

28544814
体内研究 皮下接种DU-145 Luc细胞的动物肿瘤模型中,通过尾铗和发光成像测定,Topotecan处理导致肿瘤消退。未处理的对照组相关系数为0.75,Topotecan处理组为0.93。同样,对于未治疗的和Topotecan治疗的腹腔注射移植MCF-7 Luc细胞的小鼠,肿瘤的发展与退化可使用发光成像检测。[1]在严重联合免疫缺陷(SCID)的人预后不良ALL小鼠模型中,Topotecan诱发有效的抗白血病活性。Topotecan全身药物暴露时,显著增加致命剂量人白血病细胞攻击的SCID小鼠的无病生存期。[2]神经胶质瘤优先表达TRAIL R2,用Topotecan治疗显著上调其表达。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: MCF-7 Luc 和 DU-145 Luc 细胞
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96小时
  • Method: Topotecan溶解在无菌水中,物料浓度为1 mg/mL,在培养基中稀释为6 μg/mL,然后在不透明的,白色的,组织培养物处理的微孔板中以1:4连续稀释至0.1 mL/孔的终体积。MCF-7 Luc 和 DU-145 Luc细胞以3×104细胞/mL重悬浮在包含10% FBS和0.5 mg/mL Geneticin的高浓度葡萄糖DMEM中;每孔中加入100 μL细胞。板在37 °C,95% 湿度/5% CO2环境中培养4天。培养后,0.05 mL包含50 μg/mL D-荧光素的0.1 M HEPES 缓冲液(pH 7.9)加入到每个孔中。室温下培养10分钟后,培养微孔板在微孔板光度计和分子光成像仪上测量。微孔板光度计得到的结果使用不包含外源性药物的无抑制对照孔和包含ATP抑制剂的最大抑制对照孔进行计算。分子光成像法得到的结果使用5分钟发光成像得到的值类似计算。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 负荷MCF-7 Luc 或 DU-145 Luc细胞的小鼠
  • Dosages: 0.25 mg/mL
  • Administration: 腹腔注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
Saline
30 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 457.91
化学式

C23H23N3O5.HCl

CAS号 119413-54-6
储存条件 粉状
溶于溶剂
别名 Nogitecan HCl, SKFS 104864A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04156347 Recruiting Drug: Episcleral Topotecan Retinoblastoma Targeted Therapy Technologies LLC June 16 2021 Phase 1
NCT04455139 Not yet recruiting Drug: Topotecan|Drug: Melphalan Eye Cancer Retinoblastoma Prof. Beck Popovic Maja|University of Lausanne Hospitals June 1 2021 Phase 2
NCT04428879 Recruiting Drug: Topotecan Episcleral Plaque Retinoblastoma The Hospital for Sick Children June 16 2020 Phase 1
NCT03927274 Recruiting Drug: Topotecan Glioma of Brain H. Lee Moffitt Cancer Center and Research Institute June 20 2019 Early Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • 回答:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

相关Topoisomerase产品

Tags: 购买Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl供应商 | 采购Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl价格 | Topotecan (NSC609699) HCl生产 | 订购Topotecan (NSC609699) HCl | Topotecan (NSC609699) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID